Journal Article

A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate

Nyheim, Hilde, Qin, Yan, Haram, Else Marie, Hustvedt, Svein Olaf, Moritz, Joseph M.

2017

Overview

Background Absorption of EPA and DHA from Omega-3-acid ethyl ester (EE) concentrate supplements occurs most efficiently when taken in context of a fatty meal; adequate fat intake is required to release bile salts that emulsify and pancreatic enzymes that digest omega-3-containing lipids in the intestine. Current guidelines recommend reduction in fat intake and therefore there is a need to optimize the absorption of Omega-3 in those consuming low-fat or no-fat meals. To this end, BASF has developed an Absorption Acceleration Technology, a novel self-micro-emulsifying delivery system (SMEDS) formulation of highly concentrated Omega-3-acid EE which enables rapid emulsification and microdroplet formation upon entering the aqueous environment of the gut therefore enhances the absorption. Methods Two separate single dose, crossover studies were conducted to determine the relative bioavailability of omega-3-acid EE concentrate, either as a novel SMEDS formulation (PRF-021) or as control, in healthy fasted male and female adults at two dose levels (Study 1 “low dose”: 630 mg EPA + DHA in PRF-021 vs. 840 mg EPA + DHA in control; Study 2 “high dose”: 1680 mg EPA + DHA in PRF-021 vs. 3360 mg EPA + DHA in control). Blood samples were collected immediately before supplementation and at defined time intervals for 48 h. Plasma concentration of total EPA and DHA were determined for pharmacokinetic analysis, area under the curve (AUC) and maximum observed concentration (C max ) was determined. Results Total EPA plus DHA absorption from SMEDS formulation PRF-021 were 6.4 and 11.5 times higher compared to control in low- and high-dose studies respectively, determined as the ratio of baseline corrected, dose normalized AUC 0-24h of PRF-021 over that of control. EPA and DHA individually showed differing levels of enhancement: the AUC 0-24h ratio for EPA was 23.8 and 25.7 in low and high dose studies, respectively, and the AUC 0-24h ratio for DHA was 3.6 and 5.6 in low and high dose studies, respectively. C max was also increased for both EPA and DHA 2.7- to 9.2-fold. Conclusion PRF-021 is a novel SMEDS formulation of Omega-3-acid EE demonstrating a marked improvement in absorption of a single dose of EPA and DHA EE under fasted conditions. This allows adequate absorption of Omega-3 from the supplement without the requirement of a high-fat meal.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Absorption / Adult / Area Under Curve / Bile / Bioavailability / Biological Availability / Biomedical and Life Sciences / Cardiovascular disease / Clinical Nutrition / Cross-Over Studies / Dietary Supplements / Docosahexaenoic acid (DHA) / Docosahexaenoic Acids - administration & dosage / Docosahexaenoic Acids - pharmacokinetics / Drug Delivery Systems - methods / Eicosapentaenoic acid (EPA) / Eicosapentaenoic Acid - administration & dosage / Eicosapentaenoic Acid - pharmacokinetics / Emulsification / Emulsions / Esters - administration & dosage / Fasting / Fasting - physiology / Fatty acids / Female / Fish oils / Hispanic Americans / Humans / Intestinal Absorption - physiology / Life Sciences / Lipidology / Lipids / Male / Medical Biochemistry / Middle Aged / Oils & fats / Omega-3 fatty acids / Omega-3-acid ethyl ester (EE) / Pharmacokinetics / Self-micro emulsifying delivery system (SMEDS) / Studies / Supplements